Table 2.
Study Sample Characteristics
| CON (n = 32) | SCZ (n = 28) | Χ2/t Statistics | |
|---|---|---|---|
| Demographics | |||
| Age, mean (SD) | 31.46 (8.06) | 33.17 (6.63) | 0.90 |
| Gender (% male) | 53.13 | 64.29 | 0.38 |
| Parental SES, mean (SD)a | 30.08 (9.21) | 23.15 (9.87) | −2.75** |
| Duration of illness, mean years (SD) | --- | 14.57 (6.34) | --- |
| CPZeq, mean (SD) | --- | 329.79 (207.31) | --- |
| Race | |||
| % Caucasian | 50.00 | 42.90 | 0.31 |
| % African American | 34.40 | 39.30 | |
| % Other | 15.63 | 17.86 | |
| Neurocognitive Function | |||
| Global neurocognition, mean (SD) | 0.00 (0.64) | −0.90 (0.58) | −5.64*** |
| Clinical Symptomsb | |||
| Positive symptoms, mean (SD) | --- | 2.57 (1.86) | --- |
| Negative symptoms, mean (SD) | --- | 2.86 (1.08) | --- |
| Disorganized symptoms, mean (SD) | --- | 1.80 (1.29) | --- |
| Social Cognitive Measures | |||
| Social Perception, mean (SD) | 0.00 (0.86) | −0.77 (1.05) | −3.08** |
| Mentalizing, mean (SD) | 0.00 (0.87) | −1.34 (1.09) | −5.18*** |
| Functioning Measures | |||
| Social Attainment, mean (SD) | 141.34 (12.72) | 125.43 (14.93) | −4.41*** |
| Social Competence, mean (SD)c | 4.49 (0.63) | 3.19 (0.87) | −5.96*** |
Note: SCZ, schizophrenia participants; CON, controls; SES, socioeconomic status; CPZeq, chlorpromazine equivalent.
a
Completed by n = 31 CON and n = 27 SCZ
b
Based off of SAPS SANS Global Ratings
c
Completed by n = 27 CON and n = 23 SCZ
*
P < .05,
**
P < .01,
***
P < .001